Glaucoma Pipeline Insight

DelveInsight’s, “Glaucoma Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 52+ pipeline drugs in Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Glaucoma Disease Understanding

Glaucoma Overview

Glaucoma is a group of chronic, progressive optic neuropathies characterized by degeneration of retinal ganglion cells and corresponding damage to the optic nerve, leading to irreversible visual field loss. It is one of the leading causes of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most common form, followed by primary angle-closure glaucoma (PACG). The disease often progresses silently, particularly in its early stages, delaying diagnosis until substantial vision loss has occurred. Elevated intraocular pressure (IOP) is the most important modifiable risk factor, although glaucoma can also develop in individuals with normal IOP. Additional risk factors include advanced age, family history, myopia, corticosteroid use, and certain ethnic backgrounds.

The pathophysiology of glaucoma involves impaired aqueous humor drainage through the trabecular meshwork or obstruction of the anterior chamber angle, resulting in increased IOP and mechanical as well as vascular stress on the optic nerve head. This process triggers apoptosis of retinal ganglion cells, thinning of the retinal nerve fiber layer, optic disc cupping, and progressive visual field defects.

Most patients with open-angle glaucoma remain asymptomatic until peripheral vision loss becomes evident, whereas acute angle-closure glaucoma presents with sudden severe eye pain, blurred vision, halos around lights, headache, nausea, vomiting, and a red eye, requiring immediate medical attention. Early diagnosis relies on comprehensive ophthalmic evaluation, including tonometry to measure IOP, gonioscopy to assess the drainage angle, optic nerve examination, optical coherence tomography (OCT) for retinal nerve fiber layer analysis, pachymetry to measure corneal thickness, and automated visual field testing.

The primary goal of glaucoma treatment is to prevent or slow disease progression by lowering intraocular pressure and preserving visual function, as existing vision loss cannot be reversed. First-line therapy typically consists of topical ocular hypotensive medications, including prostaglandin analogs, ß-blockers, a-adrenergic agonists, carbonic anhydrase inhibitors, and Rho kinase inhibitors, used alone or in combination depending on disease severity. Laser procedures such as selective laser trabeculoplasty (SLT) and laser peripheral iridotomy are effective options for open-angle and angle-closure glaucoma, respectively. Patients with uncontrolled disease may require surgical interventions, including trabeculectomy, glaucoma drainage devices, or minimally invasive glaucoma surgery (MIGS). Lifelong monitoring with regular assessment of IOP, optic nerve structure, and visual fields is essential to optimize treatment and minimize irreversible vision loss.

"Glaucoma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glaucoma pipeline landscape is provided which includes the disease overview and Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Glaucoma Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Glaucoma.

Glaucoma Emerging Drugs Chapters

This segment of the Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glaucoma Emerging Drugs

NCX 470: Nicox Ophthalmics

NCX 470 is an investigational second-generation nitric oxide (NO)-donating prostaglandin analog being developed by Nicox Ophthalmics for the treatment of open-angle glaucoma and ocular hypertension. In addition to lowering intraocular pressure (IOP), it is designed to enhance ocular perfusion through nitric oxide donation, offering a dual mechanism of action alongside prostaglandin F2a activity. This combined approach has demonstrated the potential for superior IOP reduction compared with conventional monotherapies. The therapy is currently in the Preregistration stage of clinical development.

HUC3-637: Huons Co., Ltd

HUC3-637 is an investigational topical ophthalmic solution being developed by Huons Co., Ltd. for the treatment of primary open-angle glaucoma (POAG) and ocular hypertension. The candidate is currently being evaluated in a Phase III, multicenter, randomized, single-blind, active-controlled clinical trial comparing HUC3-637 with HUC3-637-R. Administered as an eye drop, the study's primary endpoint is the mean change in diurnal intraocular pressure (IOP) over 12 weeks, with the aim of demonstrating effective IOP reduction while maintaining an acceptable safety profile.

QLS-111: Qlaris Bio

QLS-111 is an investigational topical ophthalmic solution developed by Qlaris Bio, Inc. for the treatment of open-angle glaucoma (OAG) and normal-tension glaucoma (NTG). It is designed to improve ocular blood flow and posterior retinal perfusion while also lowering intraocular pressure, addressing both vascular dysfunction and IOP-related mechanisms of glaucoma. The candidate is currently being evaluated in a Phase II exploratory pilot study, in which patients receive sequential twice-daily dosing of 0.015% and 0.075% QLS-111 ophthalmic solution to assess its effects on retinal perfusion, vessel dilation, safety, and tolerability.

GVB-2001: IVIEW Therapeutics Inc.

GVB-2001 is an investigational gene therapy (ScAAV2-dnRhoA) developed by IVIEW Therapeutics Inc. for the treatment of primary open-angle glaucoma (POAG). It is administered as a single intracameral injection to deliver the dominant-negative RhoA (dnRhoA) gene directly to trabecular meshwork cells, with the aim of enhancing aqueous humor outflow and reducing intraocular pressure (IOP). GVB-2001 is currently being evaluated in a Phase I/II, open-label, dose-escalation proof-of-concept study assessing its safety, tolerability, and preliminary efficacy in patients with elevated IOP despite treatment with multiple IOP-lowering medications.

GAL-101: Galimedix Therapeutics

GAL-101 is an investigational topical small-molecule amyloid-ß (Aß) aggregation modulator being developed by Galimedix Therapeutics as a potential disease-modifying therapy for glaucoma. Unlike conventional glaucoma therapies that primarily lower intraocular pressure (IOP), GAL-101 targets misfolded Aß monomers to prevent the formation of neurotoxic Aß oligomers, thereby providing neuroprotection to retinal ganglion cells. The eye-drop formulation has demonstrated excellent safety and tolerability in Phase I studies involving healthy volunteers and glaucoma.

Further product details are provided in the report……..

Glaucoma Therapeutic Assessment

This segment of the report provides insights about the different Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Glaucoma

There are approx. 50+ key companies which are developing the therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. Pre-registration include, Nicox Ophthalmics.

Glaucoma Clinical Trial Phases

DelveInsight’s report covers around 52+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Glaucoma Drugs Route of Administration

Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Glaucoma Drugs Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Glaucoma Pipeline Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glaucoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Glaucoma therapeutic drugs key players involved in developing key drugs.

Glaucoma Clinical Trials Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glaucoma drugs.

Glaucoma Pipeline Report Insights

Glaucoma Pipeline Analysis
Glaucoma Therapeutic Assessment
Glaucoma Unmet Needs
Impact of Glaucoma Drugs

Glaucoma Pipeline Report Assessment

Glaucoma Pipeline Product Profiles
Glaucoma Therapeutic Assessment
Glaucoma Pipeline Assessment
Inactive Glaucoma drugs assessment
Glaucoma Unmet Needs

Key Questions Answered In The Glaucoma Pipeline Report:

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Glaucoma drugs?
How many Glaucoma drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glaucoma?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glaucoma therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Glaucoma and their status?
What are the key designations that have been granted to the emerging drugs?